The Journal of Immunology, Vol 153, Issue 2 543-553, Copyright © 1994 by American Association of Immunologists

ARTICLES

The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, and sIgM- B lymphocytes and in Burkitt's lymphoma cell lines

J Golay, E Erba, S Bernasconi, G Peri and M Introna
Institute of Pharmacological Research Mario Negri, Milan, Italy.

The A-myb gene is structurally related to the c-mby proto-oncogene, a transcription factor involved in the regulation of hemopoietic proliferation and differentiation. Recent evidence has shown that A-myb also functions as a transcriptional activator. We have previously demonstrated that A-myb RNA is not expressed in most mature human leukocytes at rest or after mitogenic or functional activation. We show here, by using cell sorting, PCR, and Western analyses that A-myb is most highly expressed in the subsets of human tonsillar B lymphocytes with the phenotypes CD38+, CD39-, and SIgM-. The preferential expression of A-myb in these populations was seen at both the RNA and protein levels. CD38 was consistently best at separating high from low A-myb-expressing cells, whereas other markers (CD10, 22, 23, 77, 11a, and 49d) did not correlate with A-myb expression. The CD38+ population expressing the highest levels of A-myb was shown to contain mostly cycling cells inasmuch as more than 95% were in the late G1, S, G2, and M phases of the cell cycle. In addition, A-myb expression always correlated with the percentage of cells in S/G2/M in the populations sorted with either CD38, CD39, or sIgM. Small resting tonsillar B lymphocytes induced to proliferate in vitro by several different polyclonal B cell activators did not, however, express detectable levels of A-myb, although these cells were demonstrated to express CD38 and enter the S/G2/M phases of the cell cycle. These data suggest that A-myb is a marker of in vivo-activated but not in vitro-activated B lymphocytes. Finally, A-myb was also found to be highly expressed in five of seven Burkitt's lymphoma lines and in none of three EBV lymphoblastoid cell lines. This finding is in agreement with the phenotype of the normal B cells that express high levels of A-myb in vivo and suggests that A-myb may be specifically induced within germinal center B cells.

This article has been cited by other articles:

				K. A. Vora, V. M. Lentz, W. Monsell, S. P. Rao, R. Mettus, A. Toscani, E. P. Reddy, and T. Manser The T Cell-Dependent B Cell Immune Response and Germinal Center Reaction Are Intact in A-myb-Deficient Mice J. Immunol., March 1, 2001; 166(5): 3226 - 3230. [Abstract] [Full Text] [PDF]

				C. A. Heckman, J. W. Mehew, G.-G. Ying, M. Introna, J. Golay, and L. M. Boxer A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells J. Biol. Chem., February 25, 2000; 275(9): 6499 - 6508. [Abstract] [Full Text] [PDF]

				G.-G. Ying, P. Proost, J. van Damme, M. Bruschi, M. Introna, and J. Golay Nucleolin, a Novel Partner for the Myb Transcription Factor Family That Regulates Their Activity J. Biol. Chem., February 11, 2000; 275(6): 4152 - 4158. [Abstract] [Full Text] [PDF]

				A. Mortellaro, S. Songia, P. Gnocchi, M. Ferrari, C. Fornasiero, R. D'Alessio, A. Isetta, F. Colotta, and J. Golay New Immunosuppressive Drug PNU156804 Blocks IL-2-Dependent Proliferation and NF-{kappa}B and AP-1 Activation J. Immunol., June 15, 1999; 162(12): 7102 - 7109. [Abstract] [Full Text] [PDF]

				J. Golay, V. Broccoli, G. Lamorte, C. Bifulco, C. Parravicini, A. Pizzey, N. S. B. Thomas, D. Delia, P. Ferrauti, D. Vitolo, et al. The A-Myb Transcription Factor Is a Marker of Centroblasts In Vivo J. Immunol., March 15, 1998; 160(6): 2786 - 2793. [Abstract] [Full Text] [PDF]

				G.-G. Ying, M. Arsura, M. Introna, and J. Golay The DNA Binding Domain of the A-MYB Transcription Factor Is Responsible for Its B Cell-specific Activity and Binds to a B Cell 110-kDa Nuclear Protein J. Biol. Chem., October 3, 1997; 272(40): 24921 - 24926. [Abstract] [Full Text] [PDF]

				F. Tedesco, M. Pausa, E. Nardon, M. Introna, A. Mantovani, and A. Dobrina The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity J. Exp. Med., May 5, 1997; 185(9): 1619 - 1628. [Abstract] [Full Text] [PDF]

				S. E. DeRocco, R. Iozzo, X. Ma, R. Schwarting, D. Peterson, and B. Calabretta Ectopic expression of A-myb in transgenic mice causes follicular hyperplasia and enhanced B lymphocyte proliferation PNAS, April 1, 1997; 94(7): 3240 - 3244. [Abstract] [Full Text] [PDF]